|Day's Range||39.25 - 41.94|
|52 Week Range||29.95 - 58.95|
|PE Ratio (TTM)||-27.45|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pacira Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to PCRX-US. Comparing the performance and risk of Pacira Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were falling 12% yesterday after the drug maker's pain medicine failed to meet a primary efficacy endpoint in one of its two Phase 3 femoral nerve block trial. As far as Davis sees it, Pacira is still "moving on to the finals," having just the right data to deliver a response to the FDA's Complete Response Letter (CRL) from back in March 2015. In other words, the drug maker will soon be re-filing its sNDA in the indication of nerve block.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Pacira Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)